Hims & Hers Health stock price forecast: $21.00 support as HIMS falls 11.02% to $22.29

Traders Union
All News
Financial News
Hims & Hers Health slides 11.02% today

Highlights

Hims & Hers Health raised $300 million via convertible senior notes to fund global expansion, the Eucalyptus acquisition, and operational technology upgrades.
Q1 2026 showed a net loss of $92.11 million and rising liabilities to $1.82 billion, driven by increased convertible debt and shrinking gross margins.
Bearish momentum dominates as $HIMS trades below key moving averages, with high volatility and an expected price range of $21.00–$24.50 over the next sessions.

Convertible debt and net loss rise as firm pivots strategy

On May 18, 2026, Hims & Hers Health announced a $300 million convertible senior notes offering due 2032, with proceeds allocated toward international expansion, the acquisition of Eucalyptus, and investment in technology and operations. The company also released Q1 2026 results, reporting a net loss of $92.11 million and earnings per share of -$0.40 on $608 million in revenue, with gross margins declining to 65% and total liabilities reaching $1.82 billion, mainly as a result of increased convertible debt. In addition, a pivot toward branded medications in the weight loss segment, alongside further expansion into new business lines and geographies, marked ongoing strategic transition.

Bearish momentum grows as price gaps below support levels

Technically, HIMS is trading well beneath the SMA-20 ($27.00), SMA-50 ($24.29), and SMA-200 ($35.63), as well as under the Ichimoku Kijun resistance at $25.58. The session began with a notable gap down from $25.05 to $23.76, and the current price action is pressed against intraday lows near $22.18. Momentum indicators are negative: MACD is neutral on the daily but strongly negative on higher timeframes; ADX at 22.59 reveals weak trend strength. RSI sits at 40.97, while CCI is deeply negative at -170.14, with both Stoch RSI and BBP confirming a pronounced oversold condition. The Awesome Oscillator also trends strongly negative, underscoring persistent bearish momentum throughout the session.

Volatility band narrows as downside risk dominates short-term outlook

In the short term, HIMS is expected to trade within a $21.00–$24.50 volatility band relative to current levels over the next five sessions, with a high probability (above 80%) of continued decline. If the stock closes above the immediate resistance at $25.58, a recovery scenario could emerge. However, if $21.00 fails to hold as support, further downside risk is likely to accelerate.

Viktoras Karapetjanc, expert at Traders Union, sees Hims & Hers Health at a pivotal stage after the $300 million convertible debt raise. He notes the company's fundamental strength lies in strategic expansion and investment, but recent operational and financial results weigh on sentiment for now. Karapetjanc believes the long-term story remains attractive if management maintains discipline through this transition phase. "If $21.00 support holds, I see tactical recovery potential as HIMS executes on growth plans and sentiment stabilizes."

Earlier, analysts noted that Hims & Hers Health faced ongoing operational challenges and persistent downside pressures, resulting in a cautiously rangebound trading outlook. The latest results and sharp technical breakdown reinforce the prevailing bearish scenario, making it critical for traders to monitor the $21.00 support threshold as a decisive level for further downside risk in the near term.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.